Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...
EurekAlert!3d
Sylvester Cancer researchers share findings in oral presentations at the ASH 2024 Annual Meeting & Exposition
Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic ...
Business Insider4d
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Upcoming oral presentation for the ALLOHA TM Phase 1 heme trial at the ... undergoing allogeneic HCT (the ALLOHA TM trial, NCT05473910). Plans to open expansion cohorts at the proposed recommended ...